ASH 2023 | Venetoclax plus azacitidine vs intensive chemotherapy induction in fit patients with AML
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses an ongoing multicenter Phase II trial (NCT04801797) investigating the use of venetoclax plus azacitidine induction versus conventional induction chemotherapy in newly diagnosed fit patients with acute myeloid leukemia (AML). This induction approach, which avoids the use of intensive chemotherapy, is currently approved in patients over 75 years of age, however Dr Fathi hopes that the findings of this randomized trial will provide evidence for the use of this less cytotoxic regimen in younger patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy and advisory activities: Amgen, Servier, Takeda, Orum, Daiichi Sankyo, Menarini, Rigel, Remix, Abbvie, Astellas, BMS, Ipsen, Gilead, Pfizer, Genentech, AstraZeneca, Autolus, Syndax
Clinical trial funding: Abbvie, Servier, BMS
